| 1 |
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians
Open access |
17 Jan 2017 |
6,689 |
| 2 |
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al. · The Lancet Oncology
Open access |
26 Oct 2014 |
5,031 |
| 3 |
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kunnathu Kumar et al. · The Lancet Oncology
|
26 Jul 2016 |
3,102 |
| 4 |
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson et al. · The Lancet
|
Sep 2020 |
2,422 |
| 5 |
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi Antero Janne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine
Open access |
29 Apr 2015 |
2,135 |
| 6 |
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja et al. · The Lancet
|
24 Jun 2021 |
1,751 |
| 7 |
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases
Paul David Brown, Kurt A. Jaeckle, Karla V. Ballman et al. · JAMA
Open access |
26 Jul 2016 |
1,689 |
| 8 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios Athanasios Dimopoulos et al. · New England Journal of Medicine
Open access |
5 Oct 2016 |
1,454 |
| 9 |
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot et al. · New England Journal of Medicine
Open access |
24 Jul 2019 |
1,396 |
| 10 |
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Joseph Antonia et al. · The Lancet Oncology
Open access |
5 Jun 2016 |
1,263 |
| 11 |
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau et al. · New England Journal of Medicine
Open access |
5 Jun 2022 |
1,239 |
| 12 |
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Ranjana H. Advani et al. · New England Journal of Medicine
Open access |
31 Oct 2018 |
1,149 |
| 13 |
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Thierry T.F. Facon et al. · New England Journal of Medicine
Open access |
29 May 2019 |
1,022 |
| 14 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al. · Blood
Open access |
22 Mar 2016 |
945 |
| 15 |
Primary Prevention of Ischemic Stroke
Larry B. Goldstein, Robert J. Adams, Kyra J. Becker et al. · Stroke
|
2001 |
908 |
| 16 |
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al. · The Lancet
|
6 Jan 2016 |
857 |
| 17 |
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Michael A. Vogelbaum et al. · Journal of Clinical Oncology
Open access |
21 Dec 2021 |
844 |
| 18 |
Results of coronary artery surgery in patients with poor left ventricular function (CASS).
Edwin L. Alderman, Lloyd D. Fisher, Paul E. Litwin et al. · Circulation
Open access |
Oct 1983 |
815 |
| 19 |
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al. · The Lancet Oncology
|
16 Dec 2019 |
814 |
| 20 |
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Sylvia Adams et al. · Annals of Oncology
Open access |
22 Nov 2018 |
810 |
| 21 |
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert John Motzer et al. · The Lancet Oncology
Open access |
16 Aug 2019 |
797 |
| 22 |
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I
Steven C. Campbell, Peter E. Clark, Sam S. Chang et al. · The Journal of Urology
|
11 Jun 2021 |
782 |
| 23 |
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Alok A. Khorana et al. · New England Journal of Medicine
Open access |
20 Feb 2019 |
725 |
| 24 |
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard, Yuebi Hu, Kathryn Finch Mileham et al. · JAMA Oncology
Open access |
2 Aug 2018 |
705 |
| 25 |
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter Michael Voorhees et al. · Blood
Open access |
23 Apr 2020 |
701 |
| 26 |
Congenital coronary arteriovenous fistula. Report of 13 patients, review of the literature and delineation of management.
R R Liberthson, Kiran B. Sagar, J P Berkoben et al. · Circulation
Open access |
May 1979 |
680 |
| 27 |
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A. Shu, Justin F. Gainor, Mark Magdi Awad et al. · The Lancet Oncology
|
7 May 2020 |
649 |
| 28 |
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Annals of Oncology
Open access |
22 Nov 2018 |
644 |
| 29 |
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum et al. · Blood
Open access |
13 Jan 2017 |
641 |
| 30 |
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
Naiyer A. Rizvi et al. · JAMA Oncology
Open access |
9 Apr 2020 |
640 |
| 31 |
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al. · Leukemia
Open access |
11 Mar 2019 |
625 |
| 32 |
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain et al. · New England Journal of Medicine
Open access |
3 Apr 2013 |
584 |
| 33 |
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Nelson Leung et al. · Nature Reviews Nephrology
ReviewOpen access |
3 Dec 2018 |
553 |
| 34 |
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michèle Cavo et al. · The Lancet Oncology
|
30 Mar 2017 |
545 |
| 35 |
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Eli L. Diamond et al. · Cancer Discovery
Open access |
13 Nov 2015 |
542 |
| 36 |
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael K. Lim et al. · Neuro-Oncology
Open access |
28 Apr 2022 |
536 |
| 37 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio M. P. Omuro et al. · Neuro-Oncology
Open access |
14 Apr 2022 |
522 |
| 38 |
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengaß et al. · The Lancet Oncology
Open access |
29 May 2019 |
519 |
| 39 |
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Paul Gerard Guy Richardson et al. · New England Journal of Medicine
Open access |
5 Jun 2022 |
494 |
| 40 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung‐Bae Kim et al. · The Lancet Oncology
Open access |
8 Aug 2017 |
480 |
| 41 |
Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline
Gregory M.M. Videtic, Jessica Scott Donington, Meredith Elana Giuliani et al. · Practical Radiation Oncology
Open access |
5 Jun 2017 |
477 |
| 42 |
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak, Sara M. Tolaney, Lee Steven Schwartzberg et al. · JAMA Oncology
Open access |
13 Jun 2019 |
457 |
| 43 |
A Review of the Evidence for the Use of Telemedicine Within Stroke Systems of Care
Lee H. Schwamm, Robert G. Holloway, Pierre Amarenco et al. · Stroke
|
8 May 2009 |
453 |
| 44 |
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
Robert Wendel Naumann, Antoine Hollebecque, Tim Meyer et al. · Journal of Clinical Oncology
Open access |
5 Sep 2019 |
443 |
| 45 |
2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices
Julia H. Indik et al. · Heart Rhythm
|
11 May 2017 |
438 |
| 46 |
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee et al. · Blood
Open access |
4 Sep 2018 |
427 |
| 47 |
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio A. Giralt, Luciano J. Costa, Jeffrey R. Schriber et al. · Transplantation and Cellular Therapy
Open access |
17 Oct 2013 |
411 |
| 48 |
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani, Brendan M. Weiss, Torben Plesner et al. · Blood
Open access |
24 May 2016 |
407 |
| 49 |
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry T.F. Facon et al. · The Lancet Oncology
Open access |
14 Oct 2021 |
375 |
| 50 |
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology
Open access |
2 Oct 2020 |
367 |